

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

30 May 2026

### The effect of probiotics on quality of life and inflammatory and oxidative stress biomarkers in patients undergoing breast cancer chemotherapy

#### Protocol summary

##### Study aim

The aim of this study was to determine the effects of probiotic supplementation on quality of life, inflammatory factors, and oxidative stress biomarkers in patients undergoing breast cancer chemotherapy.

##### Design

Parallel double-blind (both patients and researchers) randomized controlled clinical trial. Random assignment will be done by the use of computer-generated random numbers. 60 patients with breast cancer of eligible in the study will be selected. Patients will be assigned to receive either probiotic supplements and placebo.

##### Settings and conduct

Patients with breast cancer and referred to Day hospital, Tehran, Iran.

##### Participants/Inclusion and exclusion criteria

The inclusion criteria were patients with ages between 20 and 80, breast cancer without metastases, they are candidates for chemotherapy for the first time after surgery or before surgery, Breast cancer has just been diagnosed in the patient. The exclusion criteria were consuming probiotic supplements within 8 weeks prior to the study, taking other forms of probiotics including probiotic yogurt and other fermented foods, taking antioxidants supplements, patients with metabolic syndrome, patients with chronic infections.

##### Intervention groups

Patients will be assigned to receive either probiotic supplements (intervention group: n=30) and placebo (control group: n=30).

##### Main outcome variables

Quality of Life, gastrointestinal symptom, blood factors, inflammatory factors and biomarkers of oxidative stress will be measured at study baseline and end-of-trial

#### General information

##### Reason for update

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20191006045001N1**

Registration date: **2020-01-26, 1398/11/06**

Registration timing: **retrospective**

Last update: **2020-01-26, 1398/11/06**

Update count: **0**

#### Registration date

2020-01-26, 1398/11/06

#### Registrant information

##### Name

Mahtab sadat Miraftab

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 31 5534 4047

##### Email address

miraftab.mahtab@gmail.com

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2019-10-30, 1398/08/08

#### Expected recruitment end date

2019-12-30, 1398/10/09

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

The effect of probiotics on quality of life and inflammatory and oxidative stress biomarkers in patients undergoing breast cancer chemotherapy

**Public title**

The effect of probiotics in treatment of patients undergoing breast cancer chemotherapy

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Breast cancer without metastases Patients candidate for chemotherapy for the first time after surgery or before surgery. Breast cancer just diagnosed

**Exclusion criteria:**

Consuming probiotic supplements within 8 weeks prior to the study Taking other forms of probiotics including probiotic yogurt and other fermented foods Taking antioxidants supplements Patients with metabolic syndrome Patients with chronic infections

**Age**

From **20 years** old to **80 years** old

**Gender**

Female

**Phase**

3

**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

**Sample size**

Target sample size: **60**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Participants were randomly assigned to receive either probiotic (n = 30) or placebo (n = 30) based on randomized block randomization. Blocks of size 2, 4 and 6 are used. Rand software was used for randomization. Closed envelopes were used to hide the randomization process, which were opened at the time of patient's visit to minimize the gap between randomization and drug or placebo.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Randomization and allocation will be concealed from the researchers and participants until the final analyses will be completed. Another person who is not involved in the trial and not aware of random sequences, will be assigned the participants to the numbered bottles of capsules.

**Placebo**

Used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Kashan University of Medical Sciences

**Street address**

Ghotbe Ravandi Boulevard, Kashan

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Approval date**

2019-07-28, 1398/05/06

**Ethics committee reference number**

IR.KAUMS.MEDNT.REC.1398.048

**Health conditions studied****1****Description of health condition studied**

breast cancer

**ICD-10 code**

C50

**ICD-10 code description**

Malignant neoplasm of breast

**Primary outcomes****1****Description**

Quality of life of patients

**Timepoint**

At the beginning of the study and after 12 weeks of intervention

**Method of measurement**

patient health Questionnaire 9

**Secondary outcomes****1****Description**

Gastrointestinal disorders

**Timepoint**

At the beginning of the study and after 12 weeks of intervention

**Method of measurement**

Clinical examination by oncology specialist

**2****Description**

Anemia

**Timepoint**

At the beginning of the study and after 12 weeks of intervention

**Method of measurement**

CBC test ( hemoglobin<10g/dl)

### 3

#### **Description**

Leukopenia

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

CBC test (white blood cell<4000)

### 4

#### **Description**

Thrombocytopenia

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

CBC test (Platelet<100000)

### 5

#### **Description**

Nitric oxide

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

Spectrophotometry

### 6

#### **Description**

high sensitivity C-reactive protein

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

Elisa kit

### 7

#### **Description**

Glutathione

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

Spectrophotometry

### 8

#### **Description**

Malondialdehyde

#### **Timepoint**

At the beginning of the study and after 12 weeks of intervention

#### **Method of measurement**

Spectrophotometry

## **Intervention groups**

### 1

#### **Description**

Intervention group: Probiotic capsule containing 4 strains of Bifidobacterium lactis (1/8×10<sup>9</sup> units per gram), Lactobacillus acidophilus (1/8×10<sup>9</sup> units per gram), Bifidobacterium bifidum (1/8×10<sup>9</sup> units per gram) G), Bifidobacterium langum (1/8×10<sup>9</sup> units / g) daily, orally for 12 weeks.

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Control group: placebo capsules, daily, orally for 12 weeks.

#### **Category**

Placebo

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Oncology clinic of Day hospital

##### **Full name of responsible person**

Dr Masoud Fakharian

##### **Street address**

Day hospital, Valiasr Ave, Tehran, Iran

##### **City**

Tehran

##### **Province**

Tehran

##### **Postal code**

8718695511

##### **Phone**

+98 21 8879 7111

##### **Fax**

##### **Email**

info@daygeneralhospital.ir

## **Sponsors / Funding sources**

### 1

#### **Sponsor**

##### **Name of organization / entity**

Kashan University of Medical Sciences

##### **Full name of responsible person**

Dr Hamid Reza Banafshe

##### **Street address**

Ghotbe Ravandi Boulevard, Kashan

##### **City**

Kashan

##### **Province**

Isfahan

##### **Postal code**

81151-87159

**Phone**

+98 31 5554 2999

**Email**

research@kaums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kashan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Day hospital, Tehran

**Full name of responsible person**

Dr Masoud Fakharian Kashani

**Position**

Hematology and Oncology Specialist

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Hematology

**Street address**

Day Hospital, Valiasr Ave, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

8718695511

**Phone**

+98 21 8879 7111

**Email**

info@daygeneralhospital.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Dr Mohsen Taghizade

**Position**

Assistant Professor of Nutrition Sciences

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Ghotbe Ravandi Boulevard, Kashan

**City**

Kashan

**Province**

Isfahan

**Postal code**

81151-87159

**Phone**

+98 31 5554 2999

**Fax****Email**

research@kaums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Mahtab Sadat MirafTAB

**Position**

Medical student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Cardiology

**Street address**

Ghotbe Ravandi Boulevard, Kashan

**City**

Kashan

**Province**

Isfahan

**Postal code**

8718695511

**Phone**

+98 31 5534 4047

**Fax****Email**

miraftab.mahtab@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

## Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available